KRM-III

Overview

KRM-III is an orally active TCR inhibitor and NFAT inhibitor with an IC 50 of 5 μM against NFAT. KRM-III has no effect on the activation of nuclear factor-κB. KRM-III inhibits T cell proliferation induced by T cell antigen receptor stimulation. KRM-III abrogates anti-CD3 antibody-induced cell activation in vivo. KRM-III reduces paw pad swelling in delayed-type hypersensitivity induced by Bovine serum albumin ( HY-D0842 ). KRM-III alleviates the severity of experimental autoimmune encephalomyelitis (EAE) in mice. KRM-III can be used in studies related to experimental autoimmune encephalomyelitis.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > CNS Infection | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Nuclear Factor of activated T Cells (NFAT)

Product Information

• Catalog No.: HY-136427
• CAS No.: 79220-94-3
• Molecular Formula: C15H12N2S
• Molecular Weight: 252.33
• Purity: 98.08%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (9.91 mM); Clear solution
• Availability: In-stock

Source

Original product source